Francesco De Rubertis
Francesco joined Index in 1998 to help form the firm's life sciences activity. Now based in London, life sciences investments include CellZome (acquired by GSK), Egalet (NASDAQ:EGLT), GenMab (CPH:GEN), GenSight Biologics, Micromet (acquired by Amgen), Molecular Partners, Minerva Biosciences, PanGenetics (acquired by Abbott), Parallele (acquired by Affymetrix), Profibrix (acquired by The Medicines Company) and Versartis. He is on the main board of the University of Geneva. Prior to joining Index, Francesco was a postdoctoral scientist at the Whitehead Institute of the MIT, in Cambridge.
- Grew up:
- Pavia, Geneva, Cambridge (Massachusetts).
- Geneva, London